مقاله‌های دارای تعهدات انتشار عمومی - Alain Ravaudبیشتر بدانید
جای دیگری دردسترس نیست: ۲
مرور
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 …‏
BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ...‏
The Lancet 393 (10189), 2404-2415, 2019‏
تعهدات: US National Institutes of Health‏
مرور
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised …‏
K Fizazi, L Faivre, F Lesaunier, R Delva, G Gravis, F Rolland, F Priou, ...‏
The Lancet Oncology 16 (7), 787-794, 2015‏
تعهدات: Swiss Cancer League‏
جای دیگری دردسترس است: ۵۶
مرور
Nivolumab versus everolimus in advanced renal-cell carcinoma‏
RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ...‏
New England Journal of Medicine 373 (19), 1803-1813, 2015‏
تعهدات: US National Institutes of Health‏
مرور
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma‏
RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ...‏
New England Journal of Medicine 378 (14), 1277-1290, 2018‏
تعهدات: US National Institutes of Health‏
مرور
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 …‏
T Powles, I Durán, MS Van der Heijden, Y Loriot, NJ Vogelzang, ...‏
The Lancet 391 (10122), 748-757, 2018‏
تعهدات: Cancer Research UK‏
مرور
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma‏
DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ...‏
Nature medicine 24 (6), 749-757, 2018‏
تعهدات: US National Institutes of Health‏
مرور
Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy‏
A Ravaud, RJ Motzer, HS Pandha, DJ George, AJ Pantuck, A Patel, ...‏
New england journal of medicine 375 (23), 2246-2254, 2016‏
تعهدات: US National Institutes of Health‏
مرور
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised …‏
RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ...‏
The Lancet Oncology 20 (10), 1370-1385, 2019‏
تعهدات: US National Institutes of Health‏
مرور
Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study‏
AB Apolo, JR Infante, A Balmanoukian, MR Patel, D Wang, K Kelly, ...‏
Journal of Clinical Oncology 35 (19), 2117-2124, 2017‏
تعهدات: US National Institutes of Health‏
مرور
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial‏
MR Patel, J Ellerton, JR Infante, M Agrawal, M Gordon, R Aljumaily, ...‏
The Lancet Oncology 19 (1), 51-64, 2018‏
تعهدات: US National Institutes of Health‏
مرور
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study‏
C Charlier, É Perrodeau, A Leclercq, B Cazenave, B Pilmis, B Henry, ...‏
The Lancet Infectious Diseases 17 (5), 510-519, 2017‏
تعهدات: National Institute of Health and Medical Research, France‏
مرور
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial‏
T Powles, M Kockx, A Rodriguez-Vida, I Duran, SJ Crabb, ...‏
Nature medicine 25 (11), 1706-1714, 2019‏
تعهدات: Cancer Research UK‏
مرور
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆‏
T Powles, J Bellmunt, E Comperat, M De Santis, R Huddart, Y Loriot, ...‏
Annals of Oncology 33 (3), 244-258, 2022‏
تعهدات: Cancer Research UK‏
مرور
Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results‏
RJ Motzer, A Ravaud, JJ Patard, HS Pandha, DJ George, A Patel, ...‏
European urology 73 (1), 62-68, 2018‏
تعهدات: US National Institutes of Health‏
مرور
Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma‏
NM Tannir, S Signoretti, TK Choueiri, DF McDermott, RJ Motzer, A Flaifel, ...‏
Clinical Cancer Research 27 (1), 78-86, 2021‏
تعهدات: US National Institutes of Health‏
مرور
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a …‏
RJ Motzer, B Escudier, DF McDermott, OA Frontera, B Melichar, T Powles, ...‏
Journal for immunotherapy of cancer 8 (2), e000891, 2021‏
تعهدات: US National Institutes of Health‏
مرور
Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with …‏
T Powles, MR Lackner, S Oudard, B Escudier, C Ralph, JE Brown, ...‏
Journal of Clinical Oncology 34 (14), 1660-1668, 2016‏
تعهدات: US National Institutes of Health, National Institute for Health Research, UK‏
مرور
Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder‏
B Szabados, M Kockx, ZJ Assaf, PJ van Dam, A Rodriguez-Vida, I Duran, ...‏
European urology 82 (2), 212-222, 2022‏
تعهدات: Cancer Research UK‏
مرور
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double‐blind, placebo‐controlled, phase 2 study‏
B Rini, C Szczylik, NM Tannir, P Koralewski, P Tomczak, A Deptala, ...‏
Cancer 118 (24), 6152-6161, 2012‏
تعهدات: US National Institutes of Health‏
مرور
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU …‏
A Ravaud, C de la Fouchardière, P Caron, A Doussau, C Do Cao, ...‏
European Journal of Cancer 76, 110-117, 2017‏
تعهدات: National Institute of Health and Medical Research, France‏
اطلاعات انتشارات و تأمین بودجه به‌طورخودکار توسط برنامه رایانه‌ای تعیین می‌شود.